Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284141 | 0.87 | APLNR (0.55) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL11525177 | 0.82 | MEN1 (0.56) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL31347366 | 0.82 | APLNR (0.49) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL31647035 | 0.82 | APLNR (0.49) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL24395312 | 0.80 | APLNR (0.43) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL26016115 | 0.80 | APLNR (0.43) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL19983109 | 0.80 | APLNR (0.43) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL24514107 | 0.80 | APLNR (0.50) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL6635776 | 0.79 | L3MBTL1 (0.46) | GAALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL9669784 | 0.79 | APLNR (0.42) | APLNRGAAMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4420732-A2 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG Pharmaceutical Co., Ltd. (KR) | 2024-08-28 | — | — | EP | disclosed |
| EP-3233863-B1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG PHARMACEUTICAL CO LTD (KR) | 2024-04-10 | — | — | EP | disclosed |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-09-28 | — | — | US | disclosed |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2023-09-26 | — | — | US | disclosed |
| CN-107207514-B | Fused heteroaryl compounds and their use as TRK inhibitors | 康联制药有限公司 | 2020-01-24 | — | — | CN | disclosed |
| EP-3233863-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG Pharmaceutical Co., Ltd. (KR) | 2017-10-25 | — | — | EP | disclosed |
| US-9714261-B2 | Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-25 | — | — | US | disclosed |
| US-9714261-B2 | Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-25 | — | — | US | disclosed |
| US-9701681-B2 | Fused ring heteroaryl compounds and their use as Trk inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-07-11 | — | — | US | disclosed |
| US-9701681-B2 | Fused ring heteroaryl compounds and their use as Trk inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-07-11 | — | — | US | disclosed |
| US-20160326194-A1 | IONIC LIQUID SUPPORTED ORGANOTIN REAGENTS FOR THE MANUFACTURING OF RADIOPHARMACEUTICALS COMPOUNDS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-11-10 | — | — | US | disclosed |
| WO-2016097869-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-06-23 | — | — | WO | disclosed |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | HANDOK INC. (KR) | 2016-06-16 | — | — | US | disclosed |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | HANDOK INC. (KR) | 2016-06-16 | — | — | US | disclosed |
| WO-2010100144-A1 | FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20090258885-A1 | Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20080071092-A1 | Composition for dyeing keratinous fibers comprising at least one diamino-N,N-dihydropyrazolone derivative | L'OREAL S.A. | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080071092-A1 | Composition for dyeing keratinous fibers comprising at least one diamino-N,N-dihydropyrazolone derivative | KRT18, DAO, AOC1 | APLNR 965/4885GAA 4201/4885MEN1 3832/4885 |
| US-20090258885-A1 | Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis | LTC4S, LTA4H, ALOX5 | APLNR 1852/4885GAA 1662/4885MEN1 4390/4885 |
| US-20160326194-A1 | IONIC LIQUID SUPPORTED ORGANOTIN REAGENTS FOR THE MANUFACTURING OF RADIOPHARMACEUTICALS COMPOUNDS | KIT, NISCH, FLT3 | APLNR 655/4885GAA 2834/4885MEN1 17/4885 |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XPOT, XPO1, XPO5 | APLNR 3146/4885GAA 1067/4885MEN1 1085/4885 |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPOT, XPO1, XPO5 | APLNR 3146/4885GAA 1067/4885MEN1 1085/4885 |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | NR4A3, NR4A1, NR3C1 | APLNR 3036/4885GAA 4695/4885MEN1 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.